LONDON (Alliance News) - e-Therapeutics PLC Thursday said that it believes the yield of "highly active molecules" it has found through its propriety drug discovery processes represents a proportion of molecules screened that is "several orders of magnitude higher than the published ranges observed in conventional drug discovery processes".
Shares in the company are trading up 24% at 47.00 pence.
It said it is continuing to focus its discovery team on generating a number of strong candidate molecules across several disease areas. It said its discovery and development activity otherwise continues in line with its stated plans, and it will provide a further update with its full year results at the end of March.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.